Form 4: Day One Bio CEO Shifts 614K Shares in Estate Planning
Insider Transaction Report
Day One Biopharmaceuticals CEO Jeremy Bender reported gifting 614,450 shares of common stock to various grantor retained annuity trusts as part of estate planning.
Summary
- Jeremy Bender, Chief Executive Officer and Director of Day One Biopharmaceuticals, Inc. (DAWN), reported a series of transactions on November 25, 2025.
- These transactions involved the disposition of 614,450 shares of common stock from the Bender Revocable Trust and the Jeremy Bender 2022 Grantor Retained Annuity Trust.
- Concurrently, 600,000 shares of common stock were acquired by the newly established Jeremy Bender 2025 Grantor Retained Annuity Trust and the Melissa Bender 2025 Grantor Retained Annuity Trust.
- All reported transactions were coded as 'G' (Gift) and had a transaction price of $0, indicating transfers for estate planning purposes.
- Following these transactions, Jeremy Bender's total beneficial ownership across all reported entities, including direct holdings and various trusts, amounts to 1,771,553 shares of common stock.
Sentiment
Score: 5
Explanation: The filing reports routine insider transactions related to estate planning, which are generally neutral in terms of company sentiment. They do not indicate positive or negative operational performance or strategic shifts.
Future Outlook
NA
Industry Context
These transactions are typical for high-net-worth individuals like corporate executives engaging in personal estate planning, often utilizing vehicles like Grantor Retained Annuity Trusts (GRATs) to transfer wealth efficiently. They do not reflect a change in the company's operational performance or strategic direction.
Related Party Transactions
- The transactions involve transfers of common stock between Jeremy Bender and various trusts where he or his spouse serve as trustees, which are considered related party transactions in the context of beneficial ownership reporting.
Stakeholder Impact
- Shareholders: The transactions represent a shift in beneficial ownership structure for the CEO's holdings, but do not directly impact the company's operations or outstanding share count. They are generally viewed as neutral for public shareholders.
- Employees, Customers, Suppliers, Creditors: No direct impact on these stakeholders as the filing pertains to personal estate planning of an executive.
Key Dates
| Date | Description |
|---|---|
| 11/25/2025 | Date of reported stock transactions (gifts to trusts). |
| 11/26/2025 | Date the Form 4 was signed by Attorney-in-Fact. |
Recommendation
holdThe Form 4 filing details personal estate planning transactions by CEO Jeremy Bender, involving the gifting of shares to various grantor retained annuity trusts. These transactions are not indicative of the company's operational performance, financial health, or future prospects. As such, they do not warrant a change in investment recommendation based solely on this information. Investors should continue to 'hold' their position and evaluate the company based on its core business fundamentals and future financial reports.
Keywords
Day One Biopharmaceuticals, DAWN, Jeremy Bender, SEC Form 4, Insider Transaction, Estate Planning, Grantor Retained Annuity Trust, Common Stock, CEO, Director
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.